FDA approved Viridian's Lumvoa (veligrotug-vvze) for thyroid eye disease on June 26, 2026; immediate U.S. launch followed. Q2 2026 cash stood at $982 million, and elegrobart BLA submission is on track for Q1 2027.
India's drug regulator has mandated stronger safety warnings for doxycycline and carbimazole after a national review of adverse reaction reports. Doxycycline packages will now list potential mental health side effects such as anxiety and dizziness, while carbimazole will warn of a rare blood disorder.
argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.
Women with endometriosis face increased long-term risk for thyroid disorders including hypothyroidism and Graves disease, according to a 20-year retrospective study. ACOG released new clinical guidance aimed at reducing diagnostic delays through clinical diagnosis and earlier treatment initiation.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07722546 |
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old |
RECRUITING | PHASE2 |
| NCT07682896 |
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease |
RECRUITING | PHASE2 |
| NCT07570316 |
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease |
RECRUITING | PHASE3 |
| NCT07286006 |
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT07018323 |
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease |
RECRUITING | PHASE2 |
| NCT06984627 |
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease |
RECRUITING | PHASE2 |
| NCT06727604 |
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease |
RECRUITING | PHASE2 |
